ProBioGen enters into an evaluation programme with major vaccines company for the testing of cell lines
Berlin. ProBioGen AG announced that it has entered into a joint programme with Chiron vaccines, a business unit of Chiron Corporation, to evaluate ProBioGen´s vaccine cell lines for vaccine production.
Under the programme, ProBioGen will cultivate several of its new cell lines which have been derived from various primary tissues under pre-selected conditions. Chiron Vaccines will perform testing on these cell lines for comparison against currently employed vaccine cell substrates for virus propagation and productivity. Both parties reserve option rights to enter into collaboration for the further development of cell lines for specific vaccine applications.
"This Programme will underline and prove the superiority of our cell line development expertise. ProBioGen has significant know how in providing vaccine manufacturers the necessary starting material to enhance efficiency which ultimately translates into higher productivity and lower costs," said Michael Schlenk CEO of ProBioGen.
Other news from the department business & finance
